AstraZeneca to Buy ZS Pharma for $2.7 Billion in Cash Deal

AstraZeneca Plc, the U.K.’s second-largest drugmaker, agreed to buy ZS Pharma of California for $2.7 billion in cash to gain a potential blockbuster medicine for a deadly condition.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.